This report presents the results of a study that dealt specifically with effective communication around the benefit and risk balance of vaccination people’s risk perceptions around vaccines and diseases, and approaches to enhancing communication about the safety and effectiveness of vaccines.
In 2022, 27 European Union/European Economic Area (EU/EEA) countries reported 731 echinococcosis cases. Of these, 299 (41%) cases were reported as Echinococcus granulosus sensu lato, 185 (25%) as E. multilocularis and 247 (34%) as an unknown species.
ECDC, DG SANTE and EFSA, supported by a consortium composed of Epiconcept and Integrated Quality Laboratory Services (IQLS), jointly carried out a country visit to Kosovo* from 9 to 13 October 2023, which is part of ECDC’s accession support activities to contribute to the advancement of a One Health approach against antimicrobial resistance (AMR) in the Western Balkans.
This report contains genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 31 August 2023 until 31 January 2024.
The 2022–2023 ECDC PPS was the third EU-wide point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals.
This protocol describes a survey undertaken to acquire a snapshot of the distribution of Clostridioides difficile strains in tertiary acute care hospitals in the European Union/European Economic Area (EU/EEA) in 2022–2023
The objective of this review was to investigate the efficacy, effectiveness and safety of HPV vaccination in women undergoing conisation compared with those not receiving a HPV vaccination.
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses (compared to complete primary vaccination with no booster) against hospitalisation due to COVID-19 and COVID-19-related death in resident populations ≥50 years of age living in the community.